



Financial Tear Sheet

Corporate Profile

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.

Stock Information

EBS (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$59.27
Change (%)	▲ 0.24 (0.41%)
Volume	238,117
52 Week Low	\$34.56
Market Cap	\$2,964,681,547
Rolling EPS	4.35
PE Ratio	13.5845
Shares Outstanding	50,019,935

Data as of 08/17/18 4:02 p.m. ET



Recent Headlines & Events

08/17/18

Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences

08/16/18

CEPI Awards Contract Worth up to \$36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine

08/09/18

Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax

There are currently no events scheduled.

SEC Filings

Filing Date	Form
08/15/18	4
08/09/18	4
08/09/18	8-K
08/03/18	10-Q

Data provided by Nasdaq. Minimum 15 minutes delayed.

Primary IR Contact

Robert G. Burrows

Vice President,
Investor Relations

Emergent BioSolutions Inc.

Phone: (240) 631 3280

Fax: (240) 413-1917

E-mail: burrowsr@ebsi.com